Citations

Clear

3042 citation(s) found for "Kumar, S".

Quantification of Serum 1–84 Parathyroid Hormone in Patients with Hyperparathyroidism by Immunocapture In Situ Digestion Liquid Chromatography–Tandem Mass Spectrometry
Barnidge, David R. , Chen, Li-Sheng, Twentyman, Jolaine M, Cradic, Kendall W, Grebe, Stefan K., Kumar, Vivek , Singh, Ravinder

Mayo Clinic

Clinical Chemistry | December 11, 2009 | Volume: 56 | Issue: 2 | Pages: 306-313

10.1373/clinchem.2009.134643 | PMID 20007860 Get It

Abstract Background: Immunoassays specific for 1–84 parathyroid hormone (PTH) reportedly reflect the bioactivity of PTH; however, PTH immunoassays can be susceptible to interference by cross-reacting PTH fragments. In addition, these assays currently lack standardization. A methodology using immunocapture purification with liquid chromatography–tandem mass spectrometry (LC-MS/MS) detection, along with a stable isotope–labeled internal standard, may help address these issues. Methods: We isolated 1–84 PTH from 1 mL serum by immunocapture on a 6.5-mm polystyrene bead. The immobilized PTH was digested in situ and analyzed by LC-MS/MS. For quantification, we used the selected reaction monitoring response from the N-terminal tryptic peptide 1–13 PTH (1SVSEIQLMHNLGK13). Results: The linear range of the assay was 39.1–4560 ng/L, and the limit of detection and limit of quantification were 14.5 ng/L and 39.1 ng/L, respectively. The intraassay CVs ranged from 6% to 11%, and the interassay CVs ranged from 7% to 17%. Interference by PTH fragments 1–44 PTH, 7–84 PTH, 43–68 PTH, 52–84 PTH, 64–84 PTH, and PTH-related protein (PTHrP) was ≤1% to ≤0.001%. Method comparison of LC-MS/MS vs the Roche Cobas® immunoassay yielded Deming fit of LC-MS/MS = 1.01x immunoassay – 13.21. The mean bias by Bland–Altman plot was −9.4%. Conclusions: In patients with hyperparathyroidism, the immunocapture in situ digestion LC-MS/MS method can provide accurate and precise PTH results compared with immunoassay.
Production and Characterization of Monoclonal Antibodies to Human Sclerostin
Craig, Theodore A., Sommer, Stacy, Beito, Thomas G., Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Hybridoma | October 26, 2009 | Volume: 28 | Issue: 5 | Pages: 377-381

10.1089/hyb.2009.0036 | PMID 19857121 Get It

We developed and characterized monoclonal antibodies directed against the amino-terminal and carboxy-terminal regions of human and mouse sclerostin (scl). Amino-terminal and carboxy-terminal scl peptides with limited homology to scl domain-containing protein-1 were synthesized using f-moc chemistry. The peptides were conjugated to keyhole limpet hemocyanin and the conjugates were used for immunization of mice. Monoclonal antibodies were obtained and characterized using bacterially expressed and insect cell–expressed recombinant scl. The amino-terminal (IgG 2aK) and carboxy-terminal (IgG 2bK) antibodies bound bioactive sclerostin that was expressed in an insect-cell expression system with dissociation constants in the nanomolar range. The antibodies are potentially useful agents that can be used for modulating sclerostin bioactivity.
Rearrangements and Amplification of IER3 ( IEX-1 ) Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes
Steensma, David P. , Neiger, Jessemy D., Porcher, Julie C., Keats, Jonathan J. , Bergsagel, P. Leif , Dennis, Thomas R., Knudson, Ryan A., Jenkins, Robert B. , Santana-Dávila, Rafael , Kumar, Rajiv , Ketterling, Rhett P. , Bergsagel, P. Leif , Kumar, Rajiv , Ketterling, Rhett P , Keats, Jonathan J , Steensma, David P

Mayo Clinic

Cancer Research | September 22, 2009 | Volume: 69 | Issue: 19 | Pages: 7518-7523

10.1158/0008-5472.can-09-1428 | PMID 19773435 Get It

Abstract IER3 (formerly IEX-1) encodes a 27-kDa glycoprotein that regulates death receptor–induced apoptosis, interacts with NF-κB pathways, and increases expression rapidly in response to cellular stresses such as irradiation. Animal models, gene expression microarray experiments, and functional studies in cell lines have suggested a potential role for IER3 in oncogenesis, but, to date, no abnormalities of IER3 at the DNA level have been reported in patients with neoplasia. Here, we describe breakpoint cloning of a t(6;9)(p21;q34) translocation from a patient with a myelodysplastic syndrome (MDS), facilitated by conversion technology and array-based comparative genomic hybridization, which revealed a rearrangement translocating the IER3 coding region away from critical flanking/regulatory elements and to a transcript-poor chromosomal region, markedly decreasing expression. Using split-signal and locus-specific fluorescence in situ hybridization (FISH) probes, we analyzed 204 patients with diverse hematological malignancies accompanied by clonal chromosome 6p21 abnormalities, and found 8 additional patients with MDS with IER3 rearrangements (translocations or amplification). Although FISH studies on 157 additional samples from patients with MDS and a normal-karyotype were unrevealing, and sequencing the IER3 coding and proximal promoter regions of 74 MDS patients disclosed no point mutations, reverse transcription-PCR results suggested that dysregulated expression of IER3 is common in MDS (61% >4-fold increase or decrease in expression with decreased expression primarily in early MDS and increased expression primarily in later MDS progressing toward leukemia), consistent with findings in previous microarray experiments. These data support involvement of IER3 in the pathobiology of MDS. [Cancer Res 2009;69(19):7518–23]
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, Martha Q. , Hayman, Suzanne R. , Dispenzieri, Angela , Kumar, Shaji , Greipp, Philip R., Lust, John A., Russell, Stephen J. , Dingli, David , Kyle, Robert A. , Fonseca, Rafaël , Bergsagel, P. Leif , Stewart, A. Keith, Laumann, Kristina, Allred, Jacob B., Mandrekar, Sumithra J. , Rajkumar, S. Vincent , Gertz, Morie A. , Buadi, Francis K. , Roy, Vivek , Mıkhael, Joseph , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Fonseca, Rafael

Mayo Clinic

Journal of Clinical Oncology | August 31, 2009 | Volume: 27 | Issue: 30 | Pages: 5008-5014

10.1200/jco.2009.23.6802 | PMID 19720894 Get It

Purpose Thalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that produce high remission rates in the treatment of multiple myeloma. Pomalidomide is a new IMiD with high in vitro potency. We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma. Patients and Methods Pomalidomide was administered orally at a dose of 2 mg daily on days 1 through 28 of a 28-day cycle. Dexamethasone 40 mg daily was administered orally on days 1, 8, 15, and 22 of each cycle. Responses were recorded using the criteria of the International Myeloma Working Group. Results Sixty patients were enrolled. Thirty-eight patients (63%) achieved confirmed response including complete response in three patients (5%), very good partial response in 17 patients (28%), and partial response in 18 patients (30%). Responses were seen in 40% of lenalidomide-refractory patients, 37% of thalidomide-refractory patients, and 60% of bortezomib-refractory patients. Responses were seen in 74% of patients with high-risk cytogenetic or molecular markers. Toxicity consisted primarily of myelosuppression. Grade 3 or 4 hematologic toxicity consisted of anemia (5%), thrombocytopenia (3%), and neutropenia (32%). One patient (1.6%) had a thromboembolic event. The median progression-free survival time was 11.6 months and was not significantly different in patients with high-risk disease compared with patients with standard-risk disease. Conclusion The combination of pomalidomide and low-dose dexamethasone is extremely active in the treatment of relapsed multiple myeloma, including high response rates in patients refractory to other novel agents.
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
Ansell, Stephen M. , Novak, Anne J. , Kumar, Shaji , Gupta, Mamta , Kaufmann, Scott H. , Witzig, Thomas E.

Mayo Clinic

Blood | July 30, 2009 | Volume: 114 | Issue: 14 | Pages: 2926-2935

10.1182/blood-2009-05-220889 | PMID 19641186 Get It

The mammalian target of rapamycin (mTOR) has emerged as an important therapeutic target for diffuse large B-cell lymphoma (DLBCL), as recent studies have demonstrated that 30% of relapsed patients respond to mTOR inhibitors. Why some lymphomas are resistant is incompletely understood. In the present study, we demonstrated that rapamycin inhibits mTORC1 in DLBCL lines and primary tumors but is minimally cytotoxic. Subsequent investigations revealed that rapamycin also activated eIF4E and the mTORC2 target Akt, suggesting a potential mechanism of rapamycin resistance. Furthermore, knockdown of the mTORC2 component rictor, but not the mTORC1 component raptor, inhibited rapamycin-induced Akt phosphorylation in lymphoma cells. Addition of the histone deacetylase inhibitor (HDI) LBH589 (LBH) overcame rapamycin resistance by blocking mTOR, thus preventing Akt activation. Further studies support the involvement of the protein phosphatase PP1 in LBH-mediated Akt dephosphorylation, which could be mimicked by knockdown of HDAC3. This is the first demonstration that a HDI such as LBH can overcome rapamycin resistance through a phosphatase that antagonizes mTORC2 activation. These results provide a mechanistic rationale for a clinical trial of a combination of HDI and mTOR inhibitors for DLBCL.
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
Kumar, Shaji , Kyle, Robert A. , Dispenzieri, Angela , Colby, Colin , Rajkumar, S. Vincent , Chee, Cheng Ean , Larson, Dirk R. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela

Mayo Clinic

Blood | July 30, 2009 | Volume: 114 | Issue: 13 | Pages: 2617-2618

10.1182/blood-2009-01-198788 | PMID 19641191 Get It

Abstract The current definition of complete response in multiple myeloma includes a requirement for a bone marrow (BM) examination showing less than 5% plasma cells in addition to negative serum and urine immunofixation. There have been suggestions to eliminate the need for BM examinations when defining complete response. We evaluated 92 patients with multiple myeloma who achieved negative immunofixation in the serum and urine after therapy and found that 14% had BM plasma cells more than or equal to 5%. Adding a requirement for normalization of the serum-free light chain ratio to negative immunofixation studies did not negate the need for BM studies; 10% with a normal serum-free light chain ratio had BM plasma cells more than or equal to 5%. We also found that, on achieving immunofixation-negative status, patients with less than 5% plasma cells in the BM had improved overall survival compared with those with 5% or more BM plasma cells (6.2 years vs 2.3 years, respectively; P = .01).
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Kumar, Shaji , Stadtmauer, Edward A. , Harousseau, Jean Luc, Palumbo, Antonio, Bensinger, William, Comenzo, Raymond L. , Lentzsch, Suzanne , Munshi, Nikhil C. , Niesvizky, Rubén, Miguel, Jesús F. San , Bergsagel, Leif, Bladé, Joan , Tosi, Patrizia , Sonneveld, Pieter , Sezer, Orhan , Vesole, David H., Cavo, Michèle , Richardson, Paul G. , Durie, Brian G.M. , Rajkumar, S. Vincent , Bergsagel, P. Leif , Giralt, Sergio , Ludwig, Heinz , Lonial, Sagar , Anderson, Kenneth C. , Einsele, Hermann , Richardson, Paul Gerard Guy , Bergsagel, P. Leif , Rajkumar, S Vincent , San-Miguel, Jesus

Mayo Clinic

Blood | June 27, 2009 | Volume: 114 | Issue: 9 | Pages: 1729-1735

10.1182/blood-2009-04-205013 | PMID 19561323 Get It

The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization.
O1‐03‐07: Progranulin correlates with dense‐core plaque burden in Alzheimer's disease mouse models
Pereson, Sandra, Kleinberger, Gernot , Wils, Hans , McGowan, Eileen , Jucker, Mathias , Deforce, Dieter L. D. , Broeckhoven, Christine Van , Kumar‐Singh, Samir

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2009.05.211 Get It

Headaches due to giant cell arteritis following herpes zoster ophthalmicus in an elderly patient
Kosa, SC, Younge, BR, Kumar, Naveen

Mayo Clinic

Cephalalgia | May 1, 2009 | Volume: 30 | Issue: 2 | Pages: 239-241

10.1111/j.1468-2982.2009.01880.x | PMID 19438922 Get It

Herpes zoster ophthalmicus (HZO) with post-herpetic neuralgia (PHN) and giant cell arteritis (GCA) are two diseases more commonly seen in the elderly population. Each has potentially serious and preventable visual complications by differing mechanisms. Treatments for the two diseases differ. Antiviral medications are used in HZO and high-dose corticosteroids in GCA. These two entities could potentially coexist in the same patient, leading to a complicated diagnostic scenario where a potentially treatable disease could be overlooked. Here, we report a patient who was suffering from PHN following zoster ophthalmicus who developed GCA within a time frame suggesting a potential pathogenic association with the reactivation of latent varicella zoster virus (VZV). This association could be either direct with viral vessel infiltration leading to the arteritis or by an indirect dysimmune route. A pathophysiological association with VZV leading to the development of GCA is proposed.
Quantification of Urinary Albumin by Using Protein Cleavage and LC-MS/MS
Seegmiller, Jesse C. , Barnidge, David R. , Burns, Bradley E., Larson, Timothy S., Kumar, Rajiv , Lieske, John C. , Kumar, Rajiv

Mayo Clinic

Clinical Chemistry | March 27, 2009 | Volume: 55 | Issue: 6 | Pages: 1100-1107

10.1373/clinchem.2008.115543 | PMID 19325011 Get It

Abstract Background: Urinary albumin excretion is a sensitive diagnostic and prognostic marker for renal disease. Therefore, measurement of urinary albumin must be accurate and precise. We have developed a method to quantify intact urinary albumin with a low limit of quantification (LOQ). Methods: We constructed an external calibration curve using purified human serum albumin (HSA) added to a charcoal-stripped urine matrix. We then added an internal standard, 15N-labeled recombinant HSA (15NrHSA), to the calibrators, controls, and patient urine samples. The samples were reduced, alkylated, and digested with trypsin. The concentration of albumin in each sample was determined by liquid chromatography–tandem mass spectrometry (LC-MS/MS) and linear regression analysis, in which the relative abundance area ratio of the tryptic peptides 42LVNEVTEFAK51 and 526QTALVELVK534 from albumin and 15NrHSA were referenced to the calibration curve. Results: The lower limit of quantification was 3.13 mg/L, and the linear dynamic range was 3.13–200 mg/L. Replicate digests from low, medium, and high controls (n = 5) gave intraassay imprecision CVs of 2.8%–11.0% for the peptide 42LVNEVTEFAK51, and 1.9%–12.3% for the 526QTALVELVK534 peptide. Interassay imprecision of the controls for a period of 10 consecutive days (n = 10) yielded CVs of 1.5%–14.8% for the 42LVNEVTEFAK51 peptide, and 6.4%–14.1% for the 526QTALVELVK534 peptide. For the 42LVNEVTEFAK51 peptide, a method comparison between LC-MS/MS and an immunoturbidometric method for 138 patient samples gave an R2 value of 0.97 and a regression line of y = 0.99x + 23.16. Conclusions: Urinary albumin can be quantified by a protein cleavage LC-MS/MS method using a 15NrHSA internal standard. This method provides improved analytical performance in the clinically relevant range compared to a commercially available immunoturbidometric assay.